Skip to main content
Aptamer Sciences Inc logo

Aptamer Sciences Inc — Investor Relations & Filings

Ticker · 291650 ISIN · KR7291650000 KO Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2020-03-26 Regulatory Filings
Country KR South Korea
Listing KO 291650

About Aptamer Sciences Inc

https://aptsci.com/en/

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in aptamer technology. The company has established a proprietary, integrated platform for the discovery and development of aptamer-based therapeutics and diagnostics. Its primary focus is on oncology, utilizing its Aptamer-Drug Conjugate (ApDC™) platform to create targeted cancer treatments. The lead candidate, AST-201, is an ApDC targeting the GPC3 protein, which is highly expressed in solid tumors such as liver cancer. The company is advancing AST-201 through clinical trials to evaluate its safety and efficacy. The development pipeline also includes other innovative platforms like Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS), aimed at addressing unmet medical needs in hemato-oncology and other areas. Aptamer Sciences leverages its technology to develop novel therapies with the potential for high specificity and efficacy.

Recent filings

Filing Released Lang Actions
철회신고서
Regulatory Filings Classification · 1% confidence The document is a 'Withdrawal Statement' (철회신고서) filed with the Financial Services Commission in South Korea. It explicitly states that the company (Aptamer Science) is withdrawing its public offering (공모) due to a re-evaluation of the offering schedule. Since this document relates to the cancellation of a capital-raising event (securities offering) and does not fit into specific categories like M&A or dividend announcements, it falls under the 'Regulatory Filings' category as a formal regulatory notice regarding a securities filing withdrawal.
2020-03-26 Korean
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 1% confidence The document is a '증권신고서(지분증권) 정정신고' (Amendment to Securities Registration Statement) for Aptamer Sciences. It details changes to the public offering schedule, including demand forecasting dates, subscription dates, and payment dates. In the context of financial filings, a Securities Registration Statement (and its amendments) is a primary regulatory document for capital raising activities. Since it is a formal regulatory filing regarding the issuance of shares and capital structure, it falls under the 'Capital/Financing Update' category.
2020-03-06 Korean
감사보고서 (2019.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for Aptamer Science Inc. for the fiscal year ending December 31, 2019. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. It is not an Annual Report (10-K) as it lacks the broader management discussion and analysis (MD&A) and business overview typical of a full 10-K, and it is not an announcement (RPA) because it contains the full financial data and audit opinion. FY 2019
2020-03-04 Korean
증권신고서(지분증권)
Regulatory Filings Classification · 1% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) in South Korea. It details the issuance of new shares, investment risks, and financial information for Aptamer Sciences Inc. in preparation for a public offering (IPO). This document is a formal regulatory filing required for capital raising and does not fit into the specific categories of annual reports, earnings releases, or simple announcements. Given the nature of the document as a formal registration statement for securities, it is classified as a Regulatory Filing (RNS).
2020-02-21 Korean
감사보고서 (2018.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for Aptamer Sciences, covering the fiscal year 2018. It includes the independent auditor's report from Samil PricewaterhouseCoopers, the financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes. It is not an Annual Report (10-K) as it lacks the comprehensive management discussion and analysis (MD&A) and business overview typical of a full 10-K, and it is not an announcement of a report (RPA) because it contains the full financial data and audit opinion. FY 2018
2019-04-12 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.